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Abstract
Objective: To assess the performance of a newly developed skin wipe test (SWT) for
the diagnosis of cystic fibrosis (CF).
Study Design: Spontaneously formed sweat from the forearm was wiped by a cotton
swab moistened with 100 µL of deionized (DI) water and extracted into 400 µL of
DI water (SWT). The conventional Macroduct sweat test (ST) was performed
simultaneously. SWT samples of 114 CF patients, 76 healthy carriers, and
58 controls were analyzed by capillary electrophoresis with contactless conductivity
detection and Cl−/K+ and (Cl− +Na+)/K+ ion ratios were evaluated. Chloride
concentrations from Macroduct ST were analyzed coulometrically.
Results: Analysis of 248 SWT samples and simultaneous Macroduct ST samples
showed comparable method performance. Two ion ratios, Cl−/K+ and (Cl− +Na+)/K+,
from the SWT samples and Cl− values from the ST samples were evaluated to
diagnose CF. Sensitivity of the SWT method using the Cl−/K+ ratio (cutoff value 3.9)
was 93.9%, compared to 99.1% when using the (Cl− +Na+)/K+ ratio (cutoff value 5.0)
and 98.3% in using Macroduct Cl− (cutoff value higher or equal to 60mmol/L). The
methods' specificities were 97.8%, 94.0%, and 100.0%, respectively.
Conclusions: The developed SWT method with capillary electrophoretic analysis for
CF diagnosis performs comparably to the conventional Macroduct ST. The SWT
method is simple, fast, inexpensive, and completely noninvasive. Use of an ion ratio
in obtained SWT samples is proposed as a new diagnostic parameter that shows
significant promise in CF diagnostics.
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1 | INTRODUCTION
The median life expectancy of cystic fibrosis (CF) patients has im-
proved significantly in recent years. This can be attributed in part
to timely diagnosis due to the newborn screening (NBS) programs.1
NBS in most countries relies on initial immunoreactive trypsinogen
(IRT) threshold testing that, if positive, is followed by genetic testing
and sweat test (ST).
Two collection methods are commonly applied—Gibson‐Cooke
procedure2 and Macroduct.3 Both methods start with pilocarpine
iontophoresis to stimulate sweating. The Gibson‐Cooke method uses
a filter paper to collect the induced sweat with subsequent extraction
with DI water. The Macroduct method uses a “watch type collector”
with a microconduit that is able to collect small amounts of pure
sweat. The Gibson‐Cooke method is cheaper than the Macroduct,
while both methods require trained personnel adhering to the
sampling guidelines. The sweat sample can be analyzed during the
scheduled visit, but is more often transported to a biochemical
laboratory for analysis.
Although ST is currently the gold standard, obtaining a sweat
specimen for chloride measurement can be sometimes challenging,
especially in young infants. Some concerns about ST were raised in a
recent overview article on ST practice in Europe.4 First, it was re-
ported that in more than 37% of the CF centers the cost per sweat
analysis using the Macroduct device exceeds the reimbursement.4
Conversion of laboratory equipment to the new (Macroduct) method
and the need for repeated testing when the collection procedure
yields insufficient sweat quantity also contribute to increased cost.
Second, the biological variability of sweat chloride can be as high as
18.2 mmol/L.5 This variability of the ST may jeopardize a proper in-
terpretation of the results, especially when the sweat chloride con-
centration falls within the gray zone (ie, 30‐59mmol/L chloride).
A retrospective study of 197 persons with repeated ST resulted in
reclassification of the outcome in 55 studied subjects (28%).5 The
repeated sweat chloride concentration in patients with CF and
G551D mutation assigned to placebo showed similar variability
(±20mmol/L).6 This variability may have significant implications for
clinical trials and monitoring of therapy outcomes having sweat
chloride concentration as an endpoint.
Alternatives to the ST method exist, such as the measurement of
sweat conductivity,7,8 use of sodium cation instead of chloride,9‐13 and
use of various wearable devices for online monitoring of sweat
chloride.14‐16 Unfortunately, in all of the aforementioned tests, sweat
induction by pilocarpine iontophoresis before sweat collection is required.
In a quest to simplify the whole sweat sampling procedure, we
recently developed a method briefly named skin wipe test (SWT).17,18
In SWT, on the contrary to Gibson‐Cooke or Macroduct methods, the
unstimulated, spontaneously formed sweat is collected by a cotton
swab moistened with deionized (DI) water and extracted. The col-
lection procedure is completely noninvasive, simple, and fast, taking
approximately one fifth of the time required for the conventional
sweat collection (Macroduct, Gibson‐Cooke) and it is also sig-
nificantly cheaper. SWT can be performed by the trained personnel
during scheduled patient visit. One can obtain a specimen sample
virtually at any time, even from very young infants not fulfilling the
guidelines criteria for weight and age 19 and from those having very
low perspiration rates. Evaluation by capillary electrophoresis with
contactless conductivity detection (CE‐C4D), typically performed in
the biochemical laboratory, allows analysis of the whole “sweat
ionome.” In this study, we present a comprehensive study of the
developed SWT method, using SWT samples from a large number of
participants collected at multiple CF centers. A total of 248 samples
from CF patients, healthy carriers, and controls were analyzed.
We propose the use of SWT sampling with the extended ion ratio,
defined as (Cl− +Na+)/K+, and a cutoff value of 5.0 as a new
diagnostic approach in CF diagnostics. Our approach provides a
suitable alternative to the conventional ST method offering similar
performance but several advantages.
2 | MATERIALS AND METHODS
This was a cross‐sectional diagnostic study conducted between
2016 and 2019 with the participation of three CF centers in
Brno, Czech Republic; Prague, Czech Republic; and Kecskemét,
Hungary. All patients referred to the laboratories in the study
period either had positive NBS result (IRT level > 65 ng/mL), were
referred due to suspicion of CF, or were already registered CF
patients. The study protocol was reviewed and approved by the
Ethical Committees of the participating centers. Written in-
formed consent was obtained from all participants. All samples
were blinded during the analyses. In total 248 participants were
included into the study: 114 CF patients, 76 healthy carriers, and
58 control individuals.
The CF cohort was defined as patients with two CF‐causing
cystic fibrosis transmembrane conductance regulator (CFTR) muta-
tions and positive ST (sweat chloride higher or equal to 60mmol/L).
In case of borderline ST (30‐59mmol/L) subjects were classified as
CF group based on typical clinical features (signs of pancreatic
insufficiency, signs of CF lung disease, cultivation of Pseudomonas
aeruginosa from sputum, etc) confirmed by a CF specialist.
The healthy carrier cohort was defined as individuals identified
by neonatal screening (IRT level > 65 ng/mL and DNA analysis of
50 most frequent mutations) as carriers of one CFTR mutation with
negative ST (sweat chloride < 30mmol/L) and no clinical signs of CF
confirmed by a CF specialist.
The control cohort was defined as individuals who were not
identified by neonatal screening (low IRT) and who had a negative ST
(sweat chloride < 30mmol/L). These individuals were not seen by a
CF specialist and did not have a DNA analysis. Table 1 details
characteristics of the study cohorts. The proportions of mutations as
divided into five classes according to the primary molecular defect20
also are shown in Table 1.
2.1 | Skin wipe sample collection
SWT samples and the Macroduct ST samples were obtained at the
same time. To obtain the SWT samples, the skin of the forearm was
cleaned with ethanol followed by DI water and then dried with a
cotton pad. Spontaneous sweat formation was then permitted for at
least 3minutes. A cotton swab (Linteo, Melitrade a.s., Czech Republic,
100% cotton wool wound on a plastic stick without the use of glue)
wetted with 100 µL of DI water was used for repeated wiping (10×)
of an area of skin on the forearm (at least 10 cm2). The cotton swab
was then immersed in 400 µL of DI water, allowed to stand for
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3minutes to extract the analytes and discarded without squeezing.
All samples were stored at −20°C when not analyzed immediately.
The cotton swabs used for the SWT procedure had been cleaned
before use. A detailed description of the cleaning protocol and the
SWT guidelines are provided in the documents in the online sup-
porting information. The precleaned cotton swabs can be stored in a
closed plastic containers (for instance a 15mL centrifuge tube) for at
least 2 months, can be sent by mail to the CF center and used any
time before the expiration.
2.2 | Ion analyses of the SWT samples
Ion analyses of the SWT samples were performed using the Agilent
7100 Capillary Electrophoresis (CE) System (Agilent Technologies,
Santa Clara, CA) with ADMET contactless conductivity detector
(C4D), (Ver. 5.06; ADMET, Prague, Czech Republic) at −15 kV for
anions and +15 kV for cations. A fused silica capillary (50 μm inner
diameter/375 μm outer diameter, 40/31.5 cm total/effective length;
Microquartz GmbH, Munich, Germany) was used for the separations.
Samples were injected hydrodynamically (50mbar/5 seconds). Each
analyte concentration was analyzed on the basis of its integrated
peak area. Analysis of each sample was performed in triplicate and
the data are expressed as means. The analytical parameters of the
CE‐C4D method are summarized in Table S1 in the online supporting
information. The analyses of SWT samples were performed in one
centralized laboratory (CEITEC Masaryk University, Brno, Czech
Republic). The samples were shipped from the participating CF
centers to the analytical laboratory on dry‐ice.
2.3 | Sweat sample collection and analysis using
Macroduct
ST samples were obtained using the commercial Macroduct Sweat
Collection System3 by trained personnel while strictly adhering to
the standardized guidelines.21 Sweating was stimulated using the
pilocarpine gel discs (Pilogel) and Webster Model 3700 sweat in-
ducer (Elitech) and the induced sweat was collected by the Macro-
duct Sweat Collector device for 30minutes. The samples were then
transferred to polypropylene vials and sent to the clinical laboratory
for chloride analysis using a Sherwood Model 926A chloride analyzer
(Sherwood Scientific, Cambridge, UK). The sweat samples collected
by the Macroduct Sweat Collector were analyzed in the respective
CF centers that have certified laboratories and trained personnel,
performing more than 150 analyses per year.
2.4 | Chemicals and standards
All chemicals used for preparing the background electrolyte (BGE) and
analyte stock solutions were combined with DI water (Purite,
Neptune, Watrex, Prague, Czech Republic) and were of reagent grade.
Ten millimole per liter stock solutions of inorganic anions were
prepared from their sodium salts (chloride, nitrate, nitrite, sulfate, all
from Pliva‐Lachema, Brno, Czech Republic). Ten millimole per liter
stock solutions of inorganic cations were prepared from their chloride
salts (potassium, sodium, calcium, magnesium), except that ammonium
was prepared from ammonium fluoride (all from Pliva‐Lachema, Brno,
Czech Republic). The standard sample solutions used in the analysis
were prepared separately for anions and cations by diluting the
respective standard solutions to the required concentrations with
DI water. Background electrolyte (BGE) for CE measurements was
prepared daily by diluting 200mmol/L stock solutions of L‐histidine
(HIS; Sigma‐Aldrich) and 2‐(N‐morpholino)ethanesulfonic acid
(MES; Sigma‐Aldrich) to the final concentration of 20mmol/L. The
compound 18‐crown‐6 was prepared as a 100mmol/L stock solution
and was added to the BGE to yield the final concentration of 2mmol/L.
Cetyltrimethylammonium bromide (CTAB) was prepared from
10mmol/L stock solution and was added to the BGE to yield the final
concentration of 30 µmol/L.
The optimized BGE consisted of 20mmol/L MES, 20mmol/L HIS,
2 mmol/L 18‐Crown‐6, and 30 µmol/L CTAB. Its pH was 6.
2.5 | Data evaluation, statistics
The peak area integration was performed in OpenLAB CDS
Chemstation software (Edition C.01.07 SR2; Agilent Technologies).
The calculations of mean, median, standard deviation, and relative
standard deviation values were performed in Microsoft Excel soft-
ware. The calculations of receiver operating characteristic (ROC),




Number of subjects 114 58 76 248
Sex Male 48 37 41 126
Female 66 21 35 122
Age (years) Mean 8.3 3.5 0.3 4.7
Median 8.3 2.0 0.1 1.4
Min 0.07 0.04 0.08 0.04
Max 40.5 16.8 5.5 40.5
Mutations F508del/
F508del
47 … … …
F508del/
other
54 … … …
other/other 13 … … …
Mutation class I 12.3% … … …
II 71.1% … … …
III 1.8% … … …
IV 0.4% … … …
V 2.6% … … …
Unknown 11.8% … … …
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sensitivity, specificity, positive predictive value (PPV), and negative
predictive value (NPV) were performed using the Microsoft Excel
add‐on software XlStat (v.2014.5.03; Addinsoft, Paris, France).
3 | RESULTS
3.1 | CE‐C4D analysis of SWT samples
All 248 SWT samples collected were thawed at room temperature
and directly analyzed by CE‐C4D. When needed, the samples were
appropriately diluted with DI H2O to fall within the calibration range.
Typical electropherograms obtained from the SWT samples of a CF
patient, a healthy carrier, and a control are shown in Figure 1. All
relevant anions (Cl−) and cations (NH4
+, K+, Ca2+, Na+, Mg2+) were
analyzed in under 3minutes.
3.2 | Analysis of Cl−/K+ ratio in SWT samples
The concentrations of ions in SWT samples are calculated from the
peak areas. They are not, however, comparable between different
samples because of the various volumes of sweat spontaneously
produced and collected during the SWT procedure. For that reason,
the use of ion ratio is necessary to compare the values among
different samples. Based on our preliminary results,18 the simplest
ion ratio Cl−/K+, was tested first. The Cl−/K+ ion ratios of individual
SWT samples of the three subject groups (CF patients, healthy
carriers, and controls) are shown in Figure 2A. The Cl−/K+ ion ratio
values of CF patients ranged from 2.4 to 20.2 (mean: 6.9; median:
6.6), those of controls ranged from 0.5 to 3.8 (mean: 1.5; median: 1.4),
and those of healthy carriers ranged from 0.6 to 4.9 (mean: 1.8;
median: 1.6). Using the optimum ion ratio cutoff value of 3.9 (to yield
the highest combined sensitivity and specificity of the method), as
calculated in the XlStat software, the method's sensitivity was 93.9%
and its specificity was 97.8%. From the total of 114 CF patients,
seven had the Cl−/K+ ion ratio values below the cutoff value of 3.9.
On the other hand, none of the controls, but three healthy carriers
had Cl−/K+ ion ratio values above the established cutoff value of 3.9.
PPV and NPV were thus 97.3% and 94.9%, respectively.
3.3 | Analysis of extended (Cl− +Na+)/K+ ion ratio in
SWT samples
The extended ion ratio, defined as (Cl− +Na+)/K+ might contribute to
a better diagnostic performance. The (Cl− + Na+)/K+ ion ratios of in-
dividual SWT samples of the three subject groups are also shown in
Figure 2B. The (Cl− + Na+)/K+ ion ratio values of CF patients ranged
from 3.6 to 31.1 (mean: 10.9; median: 10.4), those of controls ranged
from 0.9 to 7.3 (mean: 2.5; median: 2.2), and those of healthy carriers
ranged from 0.9 to 9.0 (mean: 2.8; median: 2.5). When the optimum
(Cl− +Na+)/K+ ion ratio cutoff value of 5.0 (calculated in the XlStat
software) was used, high sensitivity (99.1%) and specificity (94.0%) of
the method were achieved. Using the extended ion ratio cutoff value
of 5.0, all CF patients except one were diagnosed correctly. Two
controls and six healthy carriers had extended ion ratio values above
the cutoff value. PPV and NPV were thus 93.4% and 99.2%,
respectively.
3.4 | Macroduct sweat analysis
Sweat samples collected by the Macroduct collection device at the same
time as the SWT samples were taken from all subjects. The chloride
concentrations of the 114 CF patients ranged from 36 to 138mmol/L
(mean: 96.3mmol/L; median: 97.0mmol/L), chloride concentrations of
the 58 controls ranged from 4 to 30mmol/L (mean: 12.4mmol/L;
median: 10.0mmol/L), and chloride concentrations of the 76 healthy
carriers ranged from 4 to 26.0mmol/L (mean: 9.7mmol/L; median:
9.0mmol/L). The results are shown in Figure 2C. Using the official cutoff
value for Macroduct ST higher or equal to 60mmol/L, all except two CF
patients were diagnosed correctly, while all healthy carriers and con-
trols had the chloride values below 59mmol/L. The sensitivity of the
ST method was thus 98.3% and its specificity was 100.0%. PPV and
NPV were 100.0% and 98.5%, respectively.
3.5 | Receiver operating characteristics
The graphs of ROC curves were constructed (Figure 3) to describe
the diagnostic ability of the method. The ROC curves were
F IGURE 1 Electropherograms of clinical skin wipe samples. For
each group of skin wipe extracts from CF patients, healthy CF




+) and anions (Cl−) were analyzed. Capillary electrophoresis
conditions are described in Section 2.2. CF, cystic fibrosis [Color
figure can be viewed at wileyonlinelibrary.com]
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constructed for both methods while using the ion ratio Cl−/K+
(Figure 3A) and the extended ion ratio (Cl− + Na+)/K+ (Figure 3B) as
diagnostic parameters. The cutoff values were chosen to yield the
highest possible sensitivity and specificity of the method. Graphs of
the dependencies of sensitivity and specificity of the methods on the
ion ratio Cl−/K+ cutoff values and the ion ratio (Cl− + Na+)/K+ cutoff
values are shown in Figure 3C,D.
4 | DISCUSSION
The developed SWT sampling is a very fast and simple procedure.
The SWT sample is obtained in approximately 7minutes, which
time includes the forearm cleaning, waiting period for spontaneous
sweat formation, skin wiping, and extraction into DI water. By
contrast, a complete ST sampling procedure employing pilocarpine
sweat induction and collection by Macroduct device takes approxi-
mately 45minutes. Cost of sampling also is significantly reduced
(0.1 USD/per sample with the SWT method in comparison to
approximately 30 USD/per sample with the Macroduct). The cost of
consumables for one analysis by CE and Chlorocheck Chloridometer
are comparable. The initial cost of the CE‐C4D instrument is
about three to four times higher than the price of Chlorocheck
Chloridometer used to analyze chloride in sweat samples obtained
by Macroduct device. The total price difference is approximately
28.000 USD. Considering a medium size CF center that analyzes
approximately 1000 sweat samples per year and the material saving
of 29.9 USD per sample using the SWT compared to Macroduct, the
higher acquisition cost of the instrument will be compensated for in
about 1 year or after analyzing 1000 samples.
One inherent advantage of the SWT sampling is that even
though the rate of sweating in some individuals is extremely low, the
3‐minute spontaneous sweat formation period is sufficient to obtain
a suitable sample specimen for analysis by CE‐C4D. This is due to the
high analytical sensitivity of the CE‐C4D method, which is about
1000‐fold more sensitive than is the conventional coulometric
analysis. The performance of our method is important especially for
NBS, because insufficient sweat is sometimes obtained when
collecting from infants.
The analysis of SWT samples by an automated CE‐C4D instru-
ment is principally possible in any biochemical laboratory or directly
in the CF center, in which the sampling is performed.
Figure 1 illustrates the rationale for our proposed ion ratio cal-
culation. The chloride peak in the CF patient is typically significantly
higher than is a chloride peak in either a control or a healthy carrier.
The same is noticeable also for the Na+ cation because both Cl− and
Na+ transport are strongly influenced in CF patients. When looking at
the ratio of the peak areas, it is clearly visible that for CF patients the
Cl−/K+ ratio is higher than for controls or healthy carriers.
When the Cl−/K+ ion ratio (cutoff value 3.9) was used with the
SWT samples, the sensitivity (93.9%) was lower than that of the ST
method using Cl− concentration alone (98.3%). The specificity of the
F IGURE 2 Cl−/K+ ion ratio values (top), extended (Cl− +Na+)/K+ ion
ratio values (middle) in skin wipe samples, and Cl− values in Macroduct
ST samples (bottom) of CF patients (circles), healthy controls (squares),
and healthy CF carriers (triangles). SWT samples were collected by the
skin wipe sampling procedure described in Section 2.1. and analyzed by
the capillary electrophoresis system described in Section 2.2. ST
samples were collected by the Macroduct device and analyzed by
coulometry described in Section 2.3. The diagnostic borderline values
for the Cl−/K+ ion ratio (3.9), for the (Cl− +Na+)/K+ ion ratio (5.0), and
for the Cl− value (60mmol/L) are depicted by the solid line, lower
borderline value (30mmol/L) for Macroduct ST method is depicted by
dashed line. CF, cystic fibrosis; ST, sweat test; SWT, skin wipe test
[Color figure can be viewed at wileyonlinelibrary.com]
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ST method was slightly better (100.0%) compared to the 97.8%
specificity of the SWT method. Seven CF patients had the Cl−/K+ ion
ratio lower than the cutoff value of 3.9, while showing no common
feature in terms of the type of CFTR mutation (five patients carrying
F508del/F508del, one patient carrying F508del/3849+10kbC>T, and
1 patient carrying S549N/c.4272C>G, p.Tyr1424Ter [sequence
variation]).
When Cl− concentration alone was chosen as a diagnostic
parameter with a cutoff value of higher or equal to 60mmol/L,
among the 114 samples of CF patients, 2 CF patients had Cl− con-
centration less than 59mmol/L. These two CF patients are
carrying the F508del/3849+10kbC>T mutation. The F508del/
3849+10kbC>T mutation is included in the mutation class V,
generally known to cause lower Cl− concentrations in sweat than do
more severe mutation types. All healthy carriers and control ST
samples had Cl− concentrations less than 30mmol/L (indicating
100.0% specificity of the method).
The sensitivity of the SWT method improved significantly to
99.1% when the extended ion ratio (Cl− +Na+)/K+ and a cutoff value
of 5.0 was used (Figure 3). In native sweat gland ducts, CFTR and
the epithelial Na+ channels (ENaC) reside in the same apical
membrane.22,23 Reddy and Quinton24 have shown that the con-
ductance of ENaC is strongly dependent on the CFTR Cl− channel
function, resulting in elevated concentrations of both Cl− and Na+ in
the sweat of CF patients. On the contrary, the role K+ is not clear in
CF. The use of extended ion ratio (Cl− +Na+)/K+ was thought to
improve the method sensitivity. Using the extended ion ratio and
selecting the cutoff value of 5.0 only one CF patient (F508del/
F508del) had a cutoff value below this threshold. To obtain the
highest possible sensitivity is of utmost importance in any diagnostic
method. This is especially true in the case of CF, where early diag-
nosis can improve the patient's prognosis. Some of the healthy
carriers and controls (in total seven samples) had however the
extended ion ratio higher than the cutoff value, leading to specificity
of 94.0%. However, there were more healthy CF carriers (specificity
92.1%) than controls (specificity 96.6%). The reason for the higher
number of the healthy carriers is currently unknown. One might
speculate that ion transport is somewhat influenced in some of the
healthy carriers and that these subtle changes are detected in some
individuals by the SWT method but not by the ST method. A detailed
F IGURE 3 Comparison of receiver operating characteristic curves while using Cl−/K+ ion ratio (A) and (Cl−+Na+)/K+ ion ratio (B) as
diagnostic parameters. Dependences of sensitivity and specificity on Cl−/K+ ion ratio borderline (C) and (Cl−+Na+)/K+ ion ratio borderline
(D) values are shown [Color figure can be viewed at wileyonlinelibrary.com]
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investigation of these specific cases would be required. The sensi-
tivity and specificity of a new method relies upon well‐defined
groups. The quality of information about the CF cohort and healthy
carrier cohort enabled reliable definition. The limitation of this study
is that the control group was not ideally defined, as we had no
knowledge of the individuals’ DNA backgrounds. The control group
subjects had been sent for sweat testing by their family physicians for
various reasons (mainly cough), and negative ST was considered suf-
ficient to exclude CF. Therefore, a detailed study with genotyping the
selected controls would be required and is planned in the future.
Another limitation of this study includes the different age of the
subjects in the three groups. The mean age of the control group and
the healthy carrier group was 3.5 and 0.3 years, respectively. The
mean age of the CF patient group was 8.3 years. The reason for this
difference is that the subjects in the control group and the healthy
carrier group were mainly infants captured during the NBS pro-
gramme at the age 1 year or less and only a few older children. On the
contrary, although the CF group included significant number of CF
patients captured by the NBS (<1 year of age) it was not possible to
obtain significant number of new CF patients even within the 3‐year
sampling period. Therefore, this group contains significant number of
CF patients diagnosed earlier, being between 2 and 20 years of age.
Future studies comparing age‐matched groups are planned.
In Figure 3 the ROC curves show an excellent performance of
the SWT method. A large area under the curve was found
(AUC, 0.9935‐0.9937), demonstrating an excellent capability for
distinguishing the CF from the non‐CF patients. This result demon-
strates that the use of ion ratios and extended ion ratios is excellent
for diagnostic purposes.
The SWT method with CE‐C4D analysis for diagnosis of CF is
comparable in performance to the Macroduct ST, but it offers several
unique features. First, because there is no need for sweat induction,
the entire procedure is greatly simplified and application of pilo-
carpine using iontophoresis is wholly avoided. Second, the SWT
method is inexpensive. This aspect is significant, as the savings in
diagnosis costs could be more efficiently used. For instance, more
resources could be devoted to making specific care available to more
CF patients. This aspect can be especially pertinent in developing
countries where health care spending is low. The SWT is also sig-
nificantly faster, thus reducing labor cost and allowing for more tests
to be performed in the same amount of time. Third, as discussed
above, due to the inherently low limits of detection of the CE‐C4D
analytical method and the nature of the SWT sampling method, a
specimen is always obtained, even in very young infants (the
youngest infant in this study was 15 days old). The SWT may thus be
used in specific cases when sweat is difficult to obtain, and especially
during NBS. Apart from very young infants, difficulty in obtaining
sufficient sweat occurs more often also in non‐white infants.25
Analysis of the samples can be fully automated, as commercial CE
instruments are available and the analytical cost is not significantly
higher than is the coulometric analysis presently in use. It can be
envisioned that SWT could be used in the future as a part of NBS
programs and that the results obtained could be used together with
IRT and genetic screens to preselect patients requiring a con-
firmatory ST (or repeated SWT) to verify the diagnosis. The SWT
method, therefore, evidence significant promise to become a new
parameter in CF diagnostics.
ACKNOWLEDGMENTS
The authors have no perceived conflicts of interest. The authors
acknowledge financial support from the Ministry of Health of the
Czech Republic (grant no.: NV18‐08‐00189). This study was
carried out under the project CEITEC 2020 (LQ1601) with
financial support from the Ministry of Education, Youth and





1. Castellani C, Massie J, Sontag M, Southern KW. Newborn screening
for cystic fibrosis. Lancet Respir Med. 2016;4:653‐661.
2. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat
in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis.
Pediatrics. 1959;23:545‐549.
3. ELITechGroup, Macroduct® Sweat Collection System; c2019. https://
www.elitechgroup.com/product/macroduct‐sweat‐collection‐system#
tab‐features
4. Cirilli N, Southern KW, Buzzetti R, et al. Real life practice of sweat
testing in Europe. J Cyst Fibros. 2018;17:325‐332.
5. Vermeulen F, Lebecque P, De Boeck K, Leal T. Biological variability of
the sweat chloride in diagnostic sweat tests: a retrospective analysis.
J Cyst Fibros. 2017;16:30‐35.
6. Vermeulen F, Le Camus C, Davies JC, Bilton D, Milenkovic D, De
Boeck K. Variability of sweat chloride concentration in subjects
with cystic fibrosis and G551D mutations. J Cyst Fibros. 2017;16:
36‐40.
7. Vernooij‐van Langen A, Dompeling E, Yntema JB, et al. Clinical
evaluation of the Nanoduct sweat test system in the diagnosis of
cystic fibrosis after newborn screening. Eur J Pediatr. 2015;174:
1025‐1034.
8. Lezana JL, Vargas MH, Karam‐Bechara J, Aldana RS, Furuya ME.
Sweat conductivity and chloride titration for cystic fibrosis diagnosis
in 3834 subjects. J Cyst Fibros. 2003;2:1‐7.
9. Hodson ME, Beldon I, Power R, Duncan FR, Bamber M, Batten JC.
Sweat test to diagnose cystic fibrosis in adults. Br Med J. 1983;286:
1381‐1383.
10. Mishra A, Greaves R, Massie J. The limitation of sweat electrolyte
reference intervals for the diagnosis of cystic fibrosis: a systemic
review. Clin Biochem Rev. 2007;28:60‐66.
11. Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of
cystic fibrosis in newborns through older adults: cystic Fibrosis
Foundation consensus report. J Pediatr. 2008;153(2):S4‐S14.
12. Green A, Dodds P, Pennock C. A study of sweat sodium and chloride—
criteria for the diagnosis of cystic fibrosis. Ann Clin Biochem. 1985;22:
171‐176.
13. Traeger N, Shi Q, Dozor AJ. Relationship between sweat chloride,
sodium and age in clinically obtained samples. J Cyst Fibros. 2014;
13:10‐14.
14. Choi DH, Kim JS, Cutting GR, Searson PC. Wearable potentiometric
chloride sweat sensor: the critical role of the salt bridge. Anal Chem.
2016;88:12241‐12247.
ĎURČ ET AL. | 1659
15. Choi DH, Thaxton A, Jeong IC, et al. Sweat test for cystic fibrosis:
wearable sweat sensor vs. standard laboratory test. J Cyst Fibros.
2018;17:e35‐e38.
16. Rock MJ, Makholm L, Eickhoff J. A new method of sweat testing: the
CF quantum (R) sweat test. J Cyst Fibros. 2014;13:520‐527.
17. Kuban P, Gregus M, Pokojova E, Skrickova J, Foret F. Double opposite
end injection capillary electrophoresis with contactless conductometric
detection for simultaneous determination of chloride, sodium and po-
tassium in cystic fibrosis diagnosis. J Chromatogr A. 2014;1358:293‐298.
18. Durc P, Foret F, Pokojova E, et al. New approach for cystic fibrosis
diagnosis based on chloride/potassium ratio analyzed in non‐
invasively obtained skin‐wipe sweat samples by capillary electro-
phoresis with contactless conductometric detection. Anal and Bioanal
Chem. 2017;409:3507‐3514.
19. Farrell PM, White TB, Ren CL, et al. Diagnosis of cystic fibrosis:
consensus guidelines from the cystic fibrosis foundation. J Pediatr.
2017;181:S4‐S15.e1.
20. Zielinski J, Tsui LC. Cystic fibrosis: genotypic and phenotypic varia-
tions. Annu Rev Genet. 1995;29:777‐807.
21. Castellani C, Duff AJA, Bell SC, et al. ECFS best practice guidelines:
the 2018 revision. J Cyst Fibros. 2018;17:153‐178.
22. Reddy MM, Quinton PM. Altered electrical potential profile of human
reabsorptive sweat duct cells in cystic fibrosis. Am J Physiol. 1989;257:
C722‐C727.
23. Reddy MM, Quinton PM. Deactivation of CFTR‐Cl conductance by
endogenous phosphatases in the native sweat duct. Am J Physiol.
1996;270:C474‐C480.
24. Reddy MM, Quinton PM. Functional interaction of CFTR and ENaC in
sweat glands. Pflugers Arch—Eur J. Physiol. 2003;445:499‐503.
25. Laguna TA, Lin N, Wang Q, Holme B, McNamara J, Regelmann WE.
Comparison of quantitative sweat chloride methods after positive
newborn screen for cystic fibrosis. Pediatr Pulmonol. 2012;47:
736‐742.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section.
How to cite this article: Ďurč P, Foret F, Homola L, et al. Skin
wipe test: A simple, inexpensive, and fast approach in the
diagnosis of cystic fibrosis. Pediatric Pulmonology. 2020;55:
1653–1660. https://doi.org/10.1002/ppul.24758
1660 | ĎURČ ET AL.
